The Simultaneous Treatment of PC-3 Cells with the DNA-Demethylating Agent Decitabine and S-Adenosylmethionine Leads to Synergistic Anticancer Effects
2024
Combining Decitabine and S-Adenosylmethionine for Prostate Cancer Treatment
Sample size: 3
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Schmidt Thomas, Sticht Carsten
Primary Institution: Heidelberg University
Hypothesis
Can the combination of S-adenosylmethionine (SAM) and decitabine effectively suppress prostate cancer cell functions?
Conclusion
The combination treatment with SAM and decitabine showed enhanced anticancer effects without nullifying each other.
Supporting Evidence
- Combination treatment reduced the proliferation of prostate cancer cells significantly.
- Decitabine alone increased migration and invasion, but SAM reduced these effects.
- Methylation assays showed that SAM could restore decitabine-induced demethylation of proto-oncogenes.
Takeaway
Researchers found that using two treatments together can help fight prostate cancer better than using just one treatment alone.
Methodology
Prostate cancer cells (PC-3) were treated with SAM, decitabine, or both, followed by assays for proliferation, migration, invasion, and methylation.
Limitations
The study did not perform a whole-genome methylation analysis.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website